Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum(TM)

BACKGROUND: Lenabasum is a cannabinoid type 2 receptor (CB2R) reverse agonist that demonstrates anti-inflammatory effects in vivo and in vitro in dermatomyositis (DM) and is currently being investigated for therapeutic potential. The purpose of our study is to investigate CB2R distribution as well a...

Descripción completa

Detalles Bibliográficos
Autores principales: Maddukuri, Spandana, Patel, Jay, Diaz, De Anna, Chen, Kristen L., Wysocka, Maria, Bax, Christina, Li, Yubin, Ravishankar, Adarsh, Grinnell, Madison, Zeidi, Majid, Reddy, Nithin, Concha, Josef Symon S., Bashir, Muhammad M., Okawa, Joyce, White, Barbara, Werth, Victoria P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725283/
https://www.ncbi.nlm.nih.gov/pubmed/34983619
http://dx.doi.org/10.1186/s13075-021-02665-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725283/
https://www.ncbi.nlm.nih.gov/pubmed/34983619
http://dx.doi.org/10.1186/s13075-021-02665-x

Ejemplares similares